Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP) is pleased to announce that it has filed a European application in its own name, directed to Programme 2. This programme initially targets Trigeminal Neuralgia ("TN"), and the patent application filed by the Company is directed to a composition containing Delta-9-tetrahydrocannabinol ("THC") and Cannabidiol ("CBD"). The Company intends to file an international ("PCT") patent application based on this European application within the next year.
Once the patent is granted, OCTP will benefit from exclusive rights to the use, production, and sale of the composition claimed in the patent, typically for a period of up to 20 years from the filing date. This protection potentially allows OCTP to recoup its investment in R&D and secure a competitive market advantage.review of the progress that has been made in 2023.
Read the full story here.
Date posted: 10 January 2024
Article tag: Oxford Cannabinoid Technologies
Share